Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rakovina Therapeutics Inc V.RKV

Alternate Symbol(s):  RKVTF

Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical research company. The Company is focused on the development of new cancer treatments based on novel deoxyribonucleic acid (DNA)-damage response technologies. Its drug development pipeline includes kt-2000AI and kt-3000 series. It is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential... see more

Recent & Breaking News (TSXV:RKV)

Rakovina Therapeutics Announces Private Placement Offering

GlobeNewswire 1 day ago

Rakovina Therapeutics Presents AI-Driven Drug Discovery Research at Society for Neuro-Oncology Annual Meeting

GlobeNewswire 3 days ago

Rakovina Therapeutics Announces Upcoming Poster Presentation at the 29th Annual Society for Neuro-Oncology Meeting in Houston, Texas

GlobeNewswire 8 days ago

Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR Symposium in Barcelona Spain

GlobeNewswire October 25, 2024

Rakovina Therapeutics Announces Initial Drug Candidates from Deep Docking AI Molecule Discovery Platform

GlobeNewswire October 23, 2024

Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration

GlobeNewswire September 17, 2024

Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update

GlobeNewswire August 30, 2024

Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement

GlobeNewswire July 26, 2024

Rakovina Therapeutics Provides Update on Previously Announced Private Placement

GlobeNewswire July 22, 2024

Rakovina Therapeutics Announces Second Upsizing of Private Placement

GlobeNewswire July 19, 2024

Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting

GlobeNewswire June 20, 2024

Rakovina Therapeutics Announces 2024 Q1 Financial Results and Provides Corporate Update

GlobeNewswire May 30, 2024

Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations

GlobeNewswire May 24, 2024

Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement

GlobeNewswire May 23, 2024

Rakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research

GlobeNewswire May 8, 2024

Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update

GlobeNewswire April 26, 2024

Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today

GlobeNewswire April 9, 2024

Rakovina Therapeutics To Host Informational Webinar on April 3, 2024

GlobeNewswire April 1, 2024

Rakovina Therapeutics Announces Strategic Pivot to AI

GlobeNewswire March 27, 2024

Rakovina Therapeutics Inc. Announces Q3 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 27, 2023